DES Side Effects May Cause Neurodevelopmental Problems For Generations: Study

New research highlights the serious and long-term risks associated with diethylstilbestrol (DES), which was given to millions of pregnant women between the late 1930s and early 1970s, indicating that even grandchildren of women prescribed the powerful endocrine disruptor during pregnancy have a higher risk of developing attention deficit hyperactivity disorder (ADHD). 

In a study published last month in the medical journal JAMA Pediatrics, Harvard researchers warn that DES side effects may result in multigenerational neurodevelopmental problems.

The endocrine disruptor has been linked to other health effects in the past, and was banned from the market in the 70s. However, this new research suggests that the risks not only extend to children exposed during pregnancy, but to later generations off-spring as well.

Did You Know?

AT&T Data Breach Impacts Millions of Customers

More than 73 million customers of AT&T may have had their names, addresses, phone numbers, Social Security numbers and other information released on the dark web due to a massive AT&T data breach. Lawsuits are being pursued to obtain financial compensation.

Learn More

Researchers analyzed data for more than 47,000 women in the Nurses’ Health Study II, following the grandmothers who were given DES, their children, and their grandchildren. About 2%, or 850 grandmothers, were given DES during pregnancy.

More than 106,000 grandchildren were included in the study, and roughly 5%, or 5,500 grandchildren, were diagnosed with ADHD. According to the findings, use of DES by the grandmother was associated with an 8% increased risk of ADHD among grandchildren. The risk was especially increased if DES was used during the first trimester.

“This study provides evidence that diethylstilbestrol exposure is associated with multigenerational neurodevelopmental deficits,” the researchers wrote. “The doses and potency level of environmental endocrine disruptors to which humans are exposed are lower than those of diethylstilbestrol, but the prevalence of such exposure and the possibility of cumulative action are potentially high and thus warrant consideration.”

Researchers warn the evidence indicates endocrine disruptors like DES affect neurodevelopment.

Endocrine disruptors are quite pervasive in today’s society. They are found in flame retardants on furniture and clothing, plastics, sunscreen, cosmetics, water bottles, cash register receipts, food packaging, and even in restaurant food.

They have widespread side effects, including increased risk of fibroids and endometriosis, increased risk of thyroid disease, reduced male and female fertility, and cause early menopause. One study linked prenatal exposure to endocrine disruptors to increased risk of brain development disorders.

DES was prescribed between 1938 and 1971 to pregnant women to help prevent pregnancy complications. However, a 1953 study indicated if offered no benefits, and treatment was phased out. By 1971, DES was banned because daughters of women who used DES during pregnancy developed vaginal cancer.

In 2011, researchers linked DES use to increased rates of breast cancer and infertility in user’s daughters.

Recently, a North Carolina woman sued the former manufacturers of DES, citing the drug caused breast cancer and other health problems, including bicornuate uterus, a known side effect of DES exposure.


Share Your Comments

I authorize the above comments be posted on this page*

Want your comments reviewed by a lawyer?

To have an attorney review your comments and contact you about a potential case, provide your contact information below. This will not be published.

NOTE: Providing information for review by an attorney does not form an attorney-client relationship.

This field is for validation purposes and should be left unchanged.

More Top Stories

Leadership Development Committee for Suboxone Dental Injury Lawyers Established in Federal MDL
Leadership Development Committee for Suboxone Dental Injury Lawyers Established in Federal MDL (Posted today)

The U.S. District Judge presiding over all Suboxone lawsuits has created a mentorship program to use the litigation to provide some attorneys an opportunity to gain experience in handling complex federal multidistrict litigations.

Gilead Settlement Resolves 2,625 HIV Drug Lawsuits Pending in Federal Courts for $40M
Gilead Settlement Resolves 2,625 HIV Drug Lawsuits Pending in Federal Courts for $40M (Posted 2 days ago)

Gilead says it will pay $40 million to resolve HIV drug lawsuits over Truvada, Atripla, Viread, Stribild and Complera pending in the federal court system, involving claims that the the company sat on safer formulations of the drugs for years to increase profits.